Psyence Biomedical Ltd.
PBM • Biotechnology
$4.24
▲ +0.12 (+2.91%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$6.28M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 14.62Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Mar 31, 2026, 12:00 AM UTCLast profile update: Sep 30, 2026, 12:11 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$4.24
Change2.91%
Shares Out1.48M
Market Cap$6.28M
Enterprise Value$-915.50K
52W Range1.92 - 175.78
Beta1.73
P/E-0.24
P/B0.53
P/FCF-5.96
EV/EBITDA0.43
EV/FCF0.87
Price$4.24
Change2.91%
Shares Out1.48M
Market Cap$6.28M
Enterprise Value$-915.50K
52W Range1.92 - 175.78
Beta1.73
P/E-0.24
P/B0.53
P/FCF-5.96
EV/EBITDA0.43
EV/FCF0.87
Earnings Yield-417.92%
FCF Yield-16.78%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio14.62
Quick Ratio14.62
Volume27.74K
Avg Volume86.88K
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 14.62Weak profitability
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.